820 related articles for article (PubMed ID: 25062696)
1. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease.
Hall H; Reyes S; Landeck N; Bye C; Leanza G; Double K; Thompson L; Halliday G; Kirik D
Brain; 2014 Sep; 137(Pt 9):2493-508. PubMed ID: 25062696
[TBL] [Abstract][Full Text] [Related]
2. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
3. Depletion of cholinergic neurons in the nucleus of the medial septum and the vertical limb of the diagonal band in dementia with Lewy bodies.
Fujishiro H; Umegaki H; Isojima D; Akatsu H; Iguchi A; Kosaka K
Acta Neuropathol; 2006 Feb; 111(2):109-14. PubMed ID: 16421740
[TBL] [Abstract][Full Text] [Related]
4. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
5. Hippocampal CA2 Lewy pathology is associated with cholinergic degeneration in Parkinson's disease with cognitive decline.
Liu AKL; Chau TW; Lim EJ; Ahmed I; Chang RC; Kalaitzakis ME; Graeber MB; Gentleman SM; Pearce RKB
Acta Neuropathol Commun; 2019 Apr; 7(1):61. PubMed ID: 31023342
[TBL] [Abstract][Full Text] [Related]
6. Nerve growth factor receptor immunoreactivity within the nucleus basalis (Ch4) in Parkinson's disease: reduced cell numbers and co-localization with cholinergic neurons.
Mufson EJ; Presley LN; Kordower JH
Brain Res; 1991 Jan; 539(1):19-30. PubMed ID: 1849779
[TBL] [Abstract][Full Text] [Related]
7. Alpha-synuclein pathology in the olfactory pathways of dementia patients.
Hubbard PS; Esiri MM; Reading M; McShane R; Nagy Z
J Anat; 2007 Jul; 211(1):117-24. PubMed ID: 17553102
[TBL] [Abstract][Full Text] [Related]
8. Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer's and Parkinson's disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia.
Chan-Palay V
J Comp Neurol; 1988 Jul; 273(4):543-57. PubMed ID: 2463283
[TBL] [Abstract][Full Text] [Related]
9. Intralaminar nuclei of the thalamus in Lewy body diseases.
Brooks D; Halliday GM
Brain Res Bull; 2009 Feb; 78(2-3):97-104. PubMed ID: 18804518
[TBL] [Abstract][Full Text] [Related]
10. Pedunculopontine cholinergic cell loss in hallucinating Parkinson disease patients but not in dementia with Lewy bodies patients.
Hepp DH; Ruiter AM; Galis Y; Voorn P; Rozemuller AJ; Berendse HW; Foncke EM; van de Berg WD
J Neuropathol Exp Neurol; 2013 Dec; 72(12):1162-70. PubMed ID: 24226265
[TBL] [Abstract][Full Text] [Related]
11. Impairment of the septal cholinergic neurons in MPTP-treated A30P α-synuclein mice.
Szegő ÉM; Outeiro TF; Kermer P; Schulz JB
Neurobiol Aging; 2013 Feb; 34(2):589-601. PubMed ID: 22579457
[TBL] [Abstract][Full Text] [Related]
12. The decrease of β-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies.
Beyer K; Domingo-Sàbat M; Santos C; Tolosa E; Ferrer I; Ariza A
Brain; 2010 Dec; 133(Pt 12):3724-33. PubMed ID: 20959308
[TBL] [Abstract][Full Text] [Related]
13. Cholinergic deficits and galaninergic hyperinnervation of the nucleus basalis of Meynert in Alzheimer's disease and Lewy body disorders.
Alexandris AS; Walker L; Liu AKL; McAleese KE; Johnson M; Pearce RKB; Gentleman SM; Attems J
Neuropathol Appl Neurobiol; 2020 Apr; 46(3):264-278. PubMed ID: 31454423
[TBL] [Abstract][Full Text] [Related]
14. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease.
Halliday GM; Macdonald V; Henderson JM
Brain; 2005 Oct; 128(Pt 10):2272-80. PubMed ID: 16014651
[TBL] [Abstract][Full Text] [Related]
15. Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease.
Dijkstra AA; Voorn P; Berendse HW; Groenewegen HJ; ; Rozemuller AJ; van de Berg WD
Mov Disord; 2014 Sep; 29(10):1244-51. PubMed ID: 24996051
[TBL] [Abstract][Full Text] [Related]
16. Spinal cord lesions in sporadic Parkinson's disease.
Del Tredici K; Braak H
Acta Neuropathol; 2012 Nov; 124(5):643-64. PubMed ID: 22926675
[TBL] [Abstract][Full Text] [Related]
17. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease.
McRitchie DA; Cartwright HR; Halliday GM
Exp Neurol; 1997 Mar; 144(1):202-13. PubMed ID: 9126172
[TBL] [Abstract][Full Text] [Related]
18. [Dementia and Parkinson's disease: biochemical and anatomo-clinical correlation].
Dubois B; Hauw JJ; Ruberg M; Serdaru M; Javoy-Agid F; Agid Y
Rev Neurol (Paris); 1985; 141(3):184-93. PubMed ID: 4001706
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease.
Lehéricy S; Hirsch EC; Cervera-Piérot P; Hersh LB; Bakchine S; Piette F; Duyckaerts C; Hauw JJ; Javoy-Agid F; Agid Y
J Comp Neurol; 1993 Apr; 330(1):15-31. PubMed ID: 8468401
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
